clopidogrel

Conclusion The PPI esomeprazole has no significant influence on inhibition of platelet aggregation by clopidogrel.

The invention relates to a bisulfate clopidogrel solid preparation, particles and a preparation method thereof.

The difference was primarily due to a reduction in the rate of stroke with clopidogrel.

Patients assigned the clopidogrel loading dose had slightly less platelet reactivity, but it was not significant compared with placebo.

Secondly, for those patients who do not undergo PCI, the standard dose regimen of clopidogrel is sufficient.

Cigarette smoking induces CYP1A2 and may, therefore, enhance the conversion of clopidogrel to its active metabolite.

Objectives: We hypothesized that a standardized outpatient clopidogrel desensitization protocol would be safe and effective.

Patients undergoing stent-based PCI should be treated with triple therapy consisting of aspirin, clopidogrel, and warfarin.

Experiment results show that the stability of the clopidogrel bisulfate tablet of the invention is excellent.

The combination of aspirin plus clopidogrel is not more effective than clopidogrel alone, but carries a higher bleeding risk.

Background: Clopidogrel is an anti-platelet agent which causes an increase in bleeding time.

The rates of adverse cardiovascular events were lowest in patients treated with both clopidogrel and enoxaparin, the investigators report.

Recent mechanistic studies, however, suggest that omeprazole may reduce the inhibitory effect of clopidogrel on platelet aggregation.

Clopidogrel therapy does have implications for peri-operative blood loss, but hip fracture is a complex and multifactorial condition.

Clopidogrel is not superior to aspirin in unselected stroke patients but is superior in patients at high risk of recurrence.

As demonstrated, the combination of aspirin, clopidogrel and oral anticoagulants increase three to five-fold the hemorrhagic risk.

Long-term clopidogrel therapy after percutaneous coronary intervention: the "Emperors New Clothes"

Prolonged antiplatelet therapy with clopidogrel is mandatory after implantation of drug-eluting stents.

Patients with clopidogrel resistance had high platelet aggregation and were apt to suffer from cardiovascular events.

Objective To investigate the therapeutic effect of clopidogrel on progressive ischemic cerebral apoplexy.

Objective To observe the influence of proton pump inhibitor(PPI) esomeprazole on antiplatelet effect of clopidogrel.

Objective: To assess the PPB rate and outcome and identify risk factors associated with PPB in patients taking clopidogrel.

Clopidogrel is a newer, more expensive, alternative to aspirin which may be used in some patients intolerant of aspirin.

A brief overview of drug interaction as a risk factor for clopidogrel resistance is given.

Objective To explore the effect of clopidogrel bisulfate on aspirin resistance (AR) in patients with ischemic cerebrovascular disease.

One disabling or fatal stroke would be prevented for every approximately 200 patients treated for 1 year with clopidogrel added to aspirin.

The invention also provides a preparation method of the clopidogrel bisulfate tablet.

Background: Response variability to clopidogrel therapy has been demonstrated.

The incidence of clopidogrel resistance was evaluated by the percent reduction of PAGM.

Preferred drugs in the order: first choice as clopidogrel, to aspirin second choice, third choice as ticlopidine.

In this article, we reviewed the efficacy and security of high-loading-dose of Clopidogrel in Acute Coronary Syndrome.

abstract: Objective To observe the low molecular weight heparin and aspirin and clopidogrel treatment of unstable angina pectoris.

What is the relationship between clopidogrel resistance and cardiovascular outcome?

Background: No data exist about the impact of non responsiveness to clopidogrel on the risk of DES thrombosis.

But in clinical practice, many patients take aspirin, clopidogrel or warfarin together to prevent blood clots.

Clopidogrel is metabolically activated by several hepatic cytochrome P450 (CYP) isoenzymes, including CYP1A2.

So clopidogrel could be doubly beneficial, he says.

According to the above results of optimization, the overall yield of clopidogrel hydrogen sulfate is 39%.

I think the issue of clopidogrel resistance is real and it matters, and this drug is a major advance in that regard.

Study Question: What is the evidence that a platelet rebound exists, and can it be attenuated by clopidogrel tapering?

For patients who are allergic to aspirin, we recommend clopidogrel (Grade 1A).

Conclusion Health education should be strengthened in old patients 9-12 months after PCI in order to improve their clopidogrel compliance.

On the other hand, the double dose clopidogrel and high-dose aspirin combination seemed to result in the lowest event rates.

Of 804 patients, 105 (13%) were not responsive to clopidogrel.

For example, last year the FDA added a warning to the prescribing info for the widely used anticlotting drug clopidogrel.

Clinical Study of Combine of Clopidogrel and Aspirin Therapy in Patients of Acute Myocardial Infarction with ST-Elevation

Clinical Study on Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions

A clinical study of warfarin and clopidogrel in prevention of ischemic stroke in patients with nonvalvular atrial fibrillation

Clinical study of anti-inflammatory action of clopidogrel in acute coronary syndrome

Application Of Clopidogrel In Primary Percutaneous Coronary Intervention For Acute Myocardial Infarction In The Elderly Patients

Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention

Short-term outcomes of high loading dose clopidogrel pretreatment before coronary stenting in patients with acute coronary syndromes

Application of clopidogrel in percutaneous coronary intervention for acute occlusions of coronary arteries

Evaluation of Pharmacological Property and Clinical Application of Ticlopidine and Clopidogrel

Inhibitory Effects of Aspirin, Clopidogrel, and Their Combination on the Progression of Atherosclerosis in Rabbits

Safety of combined application of clopidogrel and aspirin after percutaneous coronary intervention in old man

Addition of clopidogrel to aspirin and fibrinolytic therapy for acute myocardial infarction with ST-segment elevation

Clinical observation of combined clopidogrel and low molecular heparin in progressive ischemic stroke

Clinic Observation of the Patients with Cerebral Infarction Treated by Clopidogrel

An investigation on the influencing factors of clopidogrel resistance in patients with acute coronary syndrome

Clinical Research on Treatment of Progressive Ischemic Cerebral Apoplexy with Clopidogrel

Impact of atorvastatin on the antiplatelet activity of clopidogrel in patients with acute coronary syndromes

Percutaneous Coronary Intervention - Clopidogrel in Unstable angina to prevent Recurrent ischaemic Events

Application of clopidogrel in peri-percutaneous transluminal catheter angioplasty and stent implantation

Clinical Study on the Treatment of Acute Coronary Syndrome with Clopidogrel Aspirine and low molecular heparin

Inhibition of clopidogrel on platelet aggregation rate for patients with coronary artery disease

Efficiency analyzation of clopidogrel combined with aspirin and low molecular weight heparin in non-ST-elevation acute myocardial infraction

Effects of clopidogrel loading dose in preventing direct coronary stenting complication in 38 patients with acute myocardial infarction

Prevention and Therapy of Atherosclerosis Ischemic Disease by Clopidogrel

Effects of clopidogrel on incidence of cardiac event in patients with acute coronary syndrome with non-ST-elevation

Therapeutic effects on non- ST segment elevating acute coronary syndrome with clopidogrel

Clinic observation on longterm treatment of clopidogrel in patients with unstable angina

Effects of Clopidogrel on the Formation of Experimental Atherosclerosis

Prevalence and Influential Factor of Clopidogrel Resistance

Effect of clopidogrel treatment in patients with no-ST-elevation myocardial infarction

Effect and Safeness of Combined Application of Aspirin and Clopidogrel after Percutaneous Coronary Intervention

Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis, CARESS

Clinical Effect Assessment of Unstable Angina Treated with Clopidogrel

Clinical Observation on the Treatment of Unstable Angina Pectoris by Fluvastatin, Clopidogrel and Low Molecular Heparin

Effect of different loading dose of clopidogrel on implantation of the drug-eluting stent

Clopidogrel Cost-Effective During First Year After Acute Coronary Syndrome

An investigation on clopidogrel resistance in patients with coronary stent

Clinical Study on the Treatment of Non-ST-elevation Acute Coronary Syndrome with Clopidogrel

Study of effect of load-dose clopidogrel on unstable angina

Clopidogrel Resistance May Raise Recurrent Thrombosis Risk in MI Patients

Clinical Application of Clopidogrel and Resistance

Comparing the treatment effect of low molecular heparin and clopidogrel in patients with UAP

Graphical Synthetic Routes of Clopidogrel

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

The Application of Clopidogrel in Coronary Artery Disease

The Application of Clopidogrel in Coronary Artery Disease

Effect of clopidogrel on intimal hyperplasia of rabit aorta injured by balloon

Clinical Observation on the Effect of Clopidogrel Combined with Low Molecular Heparin in Treating Unstable Angina Pectoris

The effect of different loading doses of clopidogrel on platelet aggregation

The Effect of Clopidogrel on Plasma Lysophosphatidic Acid Levels in Patients with Transient Ischemic Attack

Hepatic injury induced by clopidogrel

Change of Plasma GMP-140 and Clinical Effect of Clopidogrel in Treating Acute Cerebral Infarction

The study on addition of clopidogrel to fibrinolytic therapy for myocardial infarction with ST-segment elevation

Introduction to synthesis route of clopidogrel